Overview

Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

This is a 24-month study of ranibizumab (2.0 mg and 1.0 mg) in subjects with polypoidal choroidal vasculopathy as diagnosed by fluorescein/indocyanine green (FA/ICG) angiography.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Hawaii Pacific Health

Collaborator:

Genentech, Inc.

Treatments:

Ranibizumab